Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 9, 2002, Pages 2969-2976

  Lalezari, Jacob P ^a   Aberg, Judith A ^a   Wang, Laurene H ^a   Wire, Mary Beth ^a   Miner, Richard ^a   Snowden, Wendy ^a   Talarico, Christine L ^a   Shaw, Shuching ^a   Jacobson, Mark A ^a   Drew, W Lawrence ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BENZIMIDAVIR; CIDOFOVIR; EFAVIRENZ; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; PLACEBO; PROTEINASE INHIBITOR; VALGANCICLOVIR; VIRUS DNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG INDUCED DISEASE; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEMEN ANALYSIS; URINALYSIS; VIRUS DETECTION; VIRUS INFECTION;

EID: 0036720595     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.9.2969-2976.2002     Document Type: Article

References (14)

1. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action
2. Susceptibility of human cytomegalovirus to cidofovir is unchanged after limited in vivo exposure to various regimens of drug
3. Development of novel benzimdazole riboside compounds for treatment of cytomegalovirus disease
4. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection
5. Antiviral testing of cytomegalovirus: Criteria for detecting resistance to antivirals
6. Human cytomegalovirus: Challenges, opportunities, and new drug development
7. Synthesis and antiviral evaluation of halogenated β-D- and -L-erythrofuranosylbenzimidazoles
8. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis
9. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication
10. (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): Results of a phase I/II study of a novel antiviral nucleotide analogue
11. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS
12. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS, a randomized, controlled trial
13. Recent advances in the therapy and prevention of CMV infections
14. Ganciclovir-resistant cytomegalovirus clinical isolates: Mode of resistance to ganciclovir